The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial
Open accessAbstract
Background There is a paucity of evidence for dose and pace of up-titration of guideline-directed medical therapies after admission to hospital for acute heart failure.Methods In this multinational, open-label, randomised, parallel-group trial (STRONG-HF), patients aged 18-85 years admitted to hospital with acute heart failure, not treated with full doses of guideline-directed drug treatment, were recruited from 87 hospitals in 14 countries. Before discharge, eligible patients were randomly assigned (1:1), stratified by left ventricular ejection fraction (≤40% vs >40%) and country, with blocks of size 30 within strata and randomly ordered sub-blocks of 2, 4, and 6, to either usual care or high-intensity care. Usual care followed usual local practice, and high-intensity care involved the up-titration of treatments to 100% of recommended doses within 2 weeks of discharge and four scheduled outpatient visits over the 2 months after discharge that closely monitored clinical status, laboratory values, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations. The primary endpoint was 180-day readmission to hospital due to heart failure or all-cause death. Efficacy and safety were assessed in the intention-to-treat (ITT) population (ie, all patients validly randomly assigned to treatment). The primary endpoint was assessed in all patients enrolled at hospitals that followed up patients to day 180. Because of a protocol amendment to the primary endpoint, the results of patients enrolled on or before this amendment were down-weighted. This study is registered with ClinicalTrials.gov, NCT03412201, and is now complete.Findings Between May 10, 2018, and Sept 23, 2022, 1641 patients were screened and 1078 were successfully randomly assigned to high-intensity care (n=542) or usual care (n=536; ITT population). Mean age was 63·0 years (SD 13·6), 416 (39%) of 1078 patients were female, 662 (61%) were male, 832 (77%) were White or Caucasian, 230 (21%) were Black, 12 (1%) were other races, one (<1%) was Native American, and one (<1%) was Pacific Islander (two [<1%] had missing data on race). The study was stopped early per the data and safety monitoring board's recommendation because of greater than expected between-group differences. As of data cutoff (Oct 13, 2022), by day 90, a higher proportion of patients in the high-intensity care group had been up-titrated to full doses of prescribed drugs (renin-angiotensin blockers 278 [55%] of 505 vs 11 [2%] of 497; β blockers 249 [49%] vs 20 [4%]; and mineralocorticoid receptor antagonists 423 [84%] vs 231 [46%]). By day 90, blood pressure, pulse, New York Heart Association class, bodyweight, and NT-proBNP concentration had decreased more in the high-intensity care group than in the usual care group. Heart failure readmission or all-cause death up to day 180 occurred in 74 (15·2% down-weighted adjusted Kaplan-Meier estimate) of 506 patients in the high-intensity care group and 109 (23·3%) of 502 patients in the usual care group (adjusted risk difference 8·1% [95% CI 2·9-13·2]; p=0·0021; risk ratio 0·66 [95% CI 0·50-0·86]). More adverse events by 90 days occurred in the high-intensity care group (223 [41%] of 542) than in the usual care group (158 [29%] of 536) but similar incidences of serious adverse events (88 [16%] vs 92 [17%]) and fatal adverse events (25 [5%] vs 32 [6%]) were reported in each group.Interpretation An intensive treatment strategy of rapid up-titration of guideline-directed medication and close follow-up after an acute heart failure admission was readily accepted by patients because it reduced symptoms, improved quality of life, and reduced the risk of 180-day all-cause death or heart failure readmission compared with usual care.Funding Roche Diagnostics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapy with dapagliflozin 10 mg o.d. vs. placebo reduced the risk of the primary outcome, a composite of worsening HF (hospitalization or an urgent visit resulting in i.v.therapy for HF) or CV death, by 26% (HR 0.74; 95% CI, 0.65-0.85).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [492]
In the citing paper
“In addition, dapagliflozin reduced all-cause mortality (HR 0.83; 95% CI, 0.71-0.97)and improved symptoms, physical function, and quality of life in patients with HFrEF.491,492”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [492]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,356
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Self-citationMedical Therapy for Heart Failure With Reduced Ejection Fraction
Greene, S. J., Butler, J., Albert, N. M., DeVore, A. D., Sharma, P. P., Duffy, C. I., Hill, C. L., McCague, K., Mi, X., Patterson, J. H., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.070 · Cited by 1,322
Voors, A. A., Angermann, C. E., Teerlink, J. R., Collins, S. P., Kosiborod, M., Biegus, J., Ferreira, J. P., Nassif, M. E., Psotka, M. A., Tromp, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01659-1 · Cited by 951
Self-citationChioncel, O., Mebazaa, A., Harjola, V., Coats, A. J. S., Piepoli, M. F., Crespo‐Leiro, M. G., Laroche, C., Seferovic, P. M., Anker, S. D., Ferrari, R., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.890 · Cited by 597
Self-citationThe Causes, Treatment, and Outcome of Acute Heart Failure in 1006 Africans From 9 Countries
Damasceno, A. A. M., Mayosi, B. M., Sani, M. U., Ogah, O. S., Mondo, C. K., Ojji, D. B., Dzudié, A., Kouam, C. K., Suliman, A., Schrueder, N., et al. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.3310 · Cited by 564
Self-citationFelker, G. M., Anstrom, K. J., Adams, K. F., Ezekowitz, J. A., Fiuzat, M., Miller, N. H., Januzzi, J. L., Mark, D. B., Piña, I. L., Passmore, G., et al. (2017) · JAMA · doi:10.1001/jama.2017.10565 · Cited by 554
Jaarsma, T. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.83 · Cited by 511
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Pocock, S. J., Carson, P., Anand, I., Doehner, W., Haass, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051783 · Cited by 435
Self-citationPitt, B., White, H. D., Nicolau, J. C., Martínez, F. A., Gheorghiade, M., Aschermann, M., van Veldhuisen, D. J., Zannad, F. M., Krum, H., Mukherjee, R., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.04.038 · Cited by 396
Packer, M., Butler, J., Zannad, F. M., Filippatos, G. S., Ferreira, J. P., Pocock, S., Carson, P. E., Anand, I. S., Doehner, W., Haass, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.121.056824 · Cited by 368
Self-citationEffects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure
Krum, H., Roecker, E. B., Mohaçsi, P., Rouleau, J. L., Tendera, M., Coats, A. J. S., Katus, H. A., Fowler, M. B., Packer, M., & for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group (2003) · JAMA · doi:10.1001/jama.289.6.712 · Cited by 312
Spall, H. G. C. V., Lee, S. F., Xie, F., Oz, U. E., Perez, R., Mitoff, P. R., Maingi, M., Tjandrawidjaja, M. C., Heffernan, M., Zia, M. I., et al. (2019) · JAMA · doi:10.1001/jama.2019.0710 · Cited by 264
Berg, D. D., Jhund, P. S., Docherty, K. F., Murphy, S. A., Verma, S., Inzucchi, S. E., Køber, L., Kosiborod, M., Langkilde, A. M., Martínez, F. A., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.7585 · Cited by 190
Self-citationGayat, É., Arrigo, M., Littnerová, S., Sato, N., Pařenica, J., Ishihara, S., Špinar, J., Mueller, C. E., Harjola, V., Lassus, J. P. E., et al. (2014) · European Journal of Heart Failure · doi:10.1002/ejhf.932 · Cited by 137
Self-citationDevore, A., Granger, B., Fonarow, G., Al-Khalidi, H., Albert, N., Lewis, E., Butler, J., Piña, I. L., Allen, L., Yancy, C., et al. (2021) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2021.8844 · Cited by 134
Kimmoun, A., Takagi, K., Gall, E., Ishihara, S., Hammoum, P., Bèze, N. E., Bourgeois, A., Chassard, G., Pegorer-Sfes, H., Gayat, É., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2103 · Cited by 112
Self-citationRao, V. N., Murray, E. M., Butler, J., Cooper, L. B., Cox, Z. L., Fiuzat, M., Green, J. B., Lindenfeld, J., McGuire, D. K., Nassif, M. E., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.08.064 · Cited by 100
Yamaguchi, T., Kitai, T., Miyamoto, T., Kagiyama, N., Okumura, T., Kida, K., Oishi, S., Akiyama, E., Suzuki, S., Yamamoto, M., et al. (2018) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2018.01.006 · Cited by 71
Kimmoun, A., Cotter, G., Davison, B. A., Takagi, K., Addad, F., Čelutkienė, J., Chioncel, O. D., Solal, A. C., Díaz, R., Damasceno, A. A. M., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1575 · Cited by 66
Self-citationLam, P. H., Packer, M., Fonarow, G. C., Faselis, C. J., Allman, R. M., Morgan, C. J., Singh, S. N., Pitt, B., & Ahmed, A. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.06.053 · Cited by 44
Joseph, S., Jeemon, P., Abdullakutty, J., Sujithkumar, S., Jayaprakash Vaikathuseril, L., Joseph, J., Mattummal, S., Punnose, E., Unni, G., Natesan, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab793 · Cited by 44
Ouwerkerk, W., Teng, T. K., Tromp, J., Tay, W. T., Cleland, J. G. F., van Veldhuisen, D. J., Dickstein, K., Ng, L. L., Lang, C. C., Anker, S. D., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1869 · Cited by 37
Self-citationLogeart, D., Berthelot, E., Bihry, N., Eschalier, R., Salvat, M., Garçon, P., Eicher, J., Cohen, A. A., Tartière, J., Samadi, A., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2357 · Cited by 30
Miró, Ò., Mueller, C. E., Martín‐Sánchez, F. J., Bueno, H., Mebazaa, A., Herrero, P., Jacob, J., Gil, V., Escoda, R., & Llorens, P. (2016) · Clinical Research in Cardiology · doi:10.1007/s00392-016-1014-9 · Cited by 28
Self-citationCarubelli, V., Lombardi, C., Specchia, C., Peveri, G., Oriecuia, C., Tomasoni, D., Pasquale, M. D., Inciardi, R. M., Garrafa, E., & Metra, M. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13223 · Cited by 23
Self-citationButler, J., Yang, M., Sawhney, B., Chakladar, S., Yang, L., & Djatche, L. M. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2252 · Cited by 23
Bistola, V., Simitsis, P., Parissis, J., Ouwerkerk, W., van Veldhuisen, D. J., Cleland, J. G. F., Anker, S. D., Samani, N. J., Metra, M., Zannad, F. M., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2219 · Cited by 17
Self-citationAmended STRONG‐HF study design
Cotter, G., Davison, B. A., Metra, M., Sliwa, K. S., Voors, A. A., Addad, F., Čelutkienė, J., Chioncel, O., Solal, A. C., Díaz, R., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2348 · Cited by 16
Self-citationBedrouni, W., Sharma, A., Pitt, B., Lam, C. S. P., Ni, J., Ferreira, J. P., McMurray, J. J. V., Giannetti, N., Girerd, N., Rossignol, P., et al. (2022) · Circulation Heart Failure · doi:10.1161/circheartfailure.121.009295 · Cited by 15
Čerlinskaitė‐Bajorė, K., Mebazaa, A., Cinotti, R., Matthay, M. A., Wussler, D. N., Gayat, É., Juknevičius, V., Kozhuharov, N., Dinort, J., Michou, E., et al. (2021) · ESC Heart Failure · doi:10.1002/ehf2.13369 · Cited by 12
Self-citationGranger, B. B., Kaltenbach, L. A., Fonarow, G. C., Allen, L. A., Lanfear, D. E., Albert, N. M., Al‐Khalidi, H. R., Butler, J., Cooper, L. B., DeWald, T. A., et al. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2022.03.356 · Cited by 12
Cited by
Sorted by citations
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad195 · Cited by 2,612
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Self-citation2025 ESC/EACTS Guidelines for the management of valvular heart disease
Praz, F., Borger, M. A., Lanz, J., Cuartas, M. M., Abreu, A., Adamo, M., Marsan, N. A., Barili, F., Bonaros, N. E., Cosyns, B., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf194 · Cited by 1,364
Self-citationKittleson, M. M., Panjrath, G. S., Amancherla, K., Davis, L. L., Deswal, A., Dixon, D. L., Januzzi, J. L., & Yancy, C. W. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.03.393 · Cited by 554
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3024 · Cited by 512
Self-citation
Metadata
- Authors
- Mebazaa, A., Davison, B., Chioncel, O., Cohen-Solal, A., Diaz, R., Filippatos, G., Metra, M., Ponikowski, P., Sliwa, K., Voors, A. A., Edwards, C., Novosadova, M., Takagi, K., Damasceno, A., Saidu, H., Gayat, E., Pang, P. S., Celutkiene, J., & Cotter, G.
- Affiliations
- Inserm (FR)
- Carol Davila University of Medicine and Pharmacy (RO)
- National and Kapodistrian University of Athens (GR)
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT)
- Wroclaw Medical University (PL)
- University of Cape Town (ZA)
- University Medical Center Groningen (NL)
- Momentum Research (US)
- Eduardo Mondlane University (MZ)
- Bayero University Kano (NG)
- Indiana University Indianapolis (US)
- Corresponding author
- Mebazaa, Alexandre
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 400
- Issue
- 10367
- Pages
- 1938-1952
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4308471536
- Cited by
- 1,123
- References
- 32
- Citations by year
- 2026: 293 · 2025: 311 · 2024: 289 · 2023: 223 · 2022: 6
- FWCI
- 144.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (am, 182 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- The Lancet (acceptedVersion)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion)
- HAL (submittedVersion)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Roche Diagnostics Corp
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- acute heart failure, guideline-directed medical therapy, high-intensity care, heart failure readmission, all-cause mortality, NT-proBNP, left ventricular ejection fraction, outpatient monitoring, hospital discharge, drug safety and tolerability, heart failure pharmacotherapy
- MeSH terms
- Mineralocorticoid Receptor Antagonists, Female, Heart Failure, Humans, Male, Middle Aged, Quality of Life, Stroke Volume, Ventricular Function, Left, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
